PCOS and Fertility: The Actual Odds, the Guideline Order, and What Helps

How Does PCOS Actually Cause Infertility?

Irregular or absent ovulation is the direct mechanism behind PCOS-related infertility, and in a cohort of 1,779 women diagnosed with PCOS and treated over a ten-year period at two Dutch university centres, that single root cause — not egg quality, not a structural problem — was the reason every participant needed fertility treatment in the first place. The chain runs like this: insulin resistance, present in most PCOS phenotypes, pushes the ovaries to overproduce androgens; those androgens, combined with an elevated baseline of luteinising hormone, interfere with the normal monthly process of one follicle being selected and matured to ovulation. Instead of one dominant follicle releasing an egg, follicles stall part-way, which is what shows up on an ultrasound as the polycystic pattern and, cycle after cycle, as an absent or unpredictable period.

This means the fertility problem in most PCOS is anovulation, a mechanical failure to release an egg on a given cycle — not a shortage of eggs. That distinction matters for the whole rest of this page, and for the full set of fertility topics this site covers beyond it: it is why ovulation induction, not egg-quantity treatment, is the guideline’s starting point, and why confirming that ovulation has actually happened is a more useful thing to track than almost anything else in early treatment. It is also why an over-the-counter ovulation predictor kit, which is built to detect a single LH surge, reads positive far more often in PCOS than it should — the baseline LH is already elevated, so the test can trigger without an egg actually being released that cycle.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same reproductive mechanism — only the label changed. This guide uses PCOS, since that is still the term most readers search.

What Are the Actual Odds of Getting Pregnant With PCOS?

Most women with PCOS who pursue treatment do conceive, and the honest numbers below are more reassuring, and more specific, than a flat “yes” or “no.” In the same 1,779-woman Dutch cohort above, 37% achieved a pregnancy that reached term within the first year of starting standardised, protocol-based treatment beginning with ovulation induction — a first-year figure, not a ceiling on anyone’s total chances if that first year does not work.

Extend the timeline and the number climbs substantially. A validation cohort of 108 treatment-naive women with anovulatory PCOS, given conventional ovulation induction starting with an oral medication and escalating to injectable gonadotropins if needed, reached a cumulative singleton live-birth rate of 60% by 12 months and 78% by 24 months. Age and weight still matter inside that average: a 25-year longitudinal, population-based comparison of 981 women with self-reported PCOS against 13,266 women without it found that women with PCOS had fewer total births by the end of their reproductive years (1.7 versus 1.9 on average), were more often nulliparous (23% versus 18%), and had their first and second children at a significantly older average age — a pattern the same study links partly to how late PCOS itself tends to be diagnosed.

Read across all four rows, the pattern is consistent rather than contradictory: PCOS lowers the speed and, on population averages, the eventual likelihood of conception somewhat — it does not make pregnancy rare. None of these are individual guarantees, and none describe someone who has not yet started any treatment.

What Does the Guideline Recommend, and in What Order?

The 2023 international evidence-based guideline sets out a stepped approach rather than a single fix, built from 254 recommendations and practice points reviewed by 39 professional and consumer organisations across 71 countries. For someone with PCOS trying to conceive, that order generally runs: improving insulin resistance through lifestyle and weight management as a foundation where relevant, a first-line ovulation-inducing medication, an insulin-sensitising option layered in or substituted depending on individual factors, and specialist-level treatment — gonadotropins or IVF — if the earlier steps do not lead to a pregnancy after a fair, monitored trial. This page describes what the guideline recommends and why; it does not replace a conversation with the clinician managing your specific case, and it deliberately does not lay out a dose or a day-by-day protocol to follow on your own.

Which Fertility Drugs Are Used for PCOS?

Two categories of fertility drug come up in PCOS treatment, and the guideline ranks them differently rather than interchangeably: letrozole and clomiphene, both used to induce ovulation, and metformin, used as an insulin-sensitising adjunct rather than a first choice for induction. What follows is how each is used and why the guideline orders them the way it does — not a dose or a regimen to follow without a prescriber.

For ovulation induction specifically, the guideline names letrozole, not the older drug clomiphene, as the first-choice medication — a landmark 750-woman trial found a live birth in 27.5% of women assigned letrozole against 19.1% on clomiphene, and that gap, replicated across other trials, is what moved the guideline’s recommendation. The fuller comparison of why that changed, and what it means if you were already offered clomiphene, is covered in depth here; the mechanism and success rates specific to letrozole are covered here.

Metformin sits differently in the order. A 2019 Cochrane review pooling multiple randomised trials of metformin for ovulation induction concluded that it may be beneficial over placebo for live birth, but that the comparison against clomiphene remains genuinely inconclusive, with results differing by body mass index and a higher rate of gastrointestinal side effects on metformin than on the guideline’s preferred first-line drug. That is why metformin functions in most guideline-based care as an adjunct considered alongside insulin-resistance management, not as the medication a clinician reaches for first to induce ovulation — a distinction explored fully here, including where it does and does not help.

Who actually pays for any of this varies enormously by country, and it’s a separate question from the clinical order above — who actually pays for fertility treatment breaks down what the NHS, Medicare, RAMQ, the HSE and US insurers each fund at every stage, since ovulation induction is covered far more often than IVF.

When Should You Seek Fertility Help, and How Soon?

Twelve months of trying without success is the general definition of infertility used to trigger a work-up, per the American Society for Reproductive Medicine’s current committee opinion — but that window shortens to six months once you are 35 or older, because reproductive time becomes a materially scarcer resource at that point regardless of the underlying cause. PCOS changes the practical calculation further: if your cycles are already absent or arriving fewer than eight times a year, that pattern is itself usually sufficient evidence that anovulation is happening, which means there is little reason to spend a full year “trying” before raising it with a clinician. The full set of timelines, including what changes them, is laid out here.

Age interacts with PCOS in a way that surprises a lot of people: ovarian reserve markers in PCOS often stay comparatively favourable for longer than in the general population, which is explored in detail here — a reassuring finding, but not a reason to delay a conversation once you are past 35 and the guideline’s six-month referral window applies. Separately, egg quantity and egg quality are not the same measurement, and a normal or even high antral follicle count in PCOS does not by itself confirm that eggs released will be capable of normal fertilisation — worth knowing before treating any single number as reassurance on its own.

While that referral clock is running, what you track matters as much as how long you wait. An irregular cycle makes a standard calendar-counting method unreliable, and a basic ovulation predictor kit built for a 28-day cycle can miss the fertile window entirely or, as covered above, signal falsely because of an already-elevated LH baseline. Which tracking method actually survives an irregular PCOS cycle, and which ones waste money, is compared here — worth sorting out before the 12-month or 6-month clock starts, not after it ends.

Does Weight Loss Actually Change the Odds?

Weight functions here as a metabolic lever on ovulation, not a moral one, and the trial evidence treats it exactly that way. A randomized trial of 149 women with infertility from PCOS and a body mass index of 27–42, assigned to 16 weeks of a lifestyle programme targeting roughly 7% weight loss, a hormonal pretreatment, or both, found that the group that lost weight achieved cumulative ovulation in 60–67% of cycles compared with 46% on hormonal pretreatment alone. Average weight loss actually achieved was 6.2%, close to the 7% target. Live birth rates favoured the weight-loss groups too (24–26% versus 12%), though that particular difference did not reach statistical significance in a trial this size (P = 0.13) — an honest limitation, not a reason to discount the ovulation result, which did reach significance.

This is a population-average finding, not a target number for any individual body, and it applies specifically to women carrying excess weight who are trying to conceive — it says nothing about someone with lean PCOS, whose fertility mechanism and management differ meaningfully from the insulin-driven pattern this trial tested — what actually helps conception with lean PCOS runs on a different hormonal driver entirely. How insulin resistance itself connects to PCOS symptoms more broadly is covered here, and the specific ovulation-restoring percentage from a larger evidence base is broken down here.

What Does the Evidence Say About Inositol and Metformin for Fertility?

Inositol’s evidence base is thinner than its marketing suggests, and the guideline’s own review says so directly. A systematic review of 30 trials and 2,230 women, conducted specifically to inform the 2023 guideline update, found some benefit from D-chiro-inositol for ovulation and from myo-inositol for certain metabolic measures, but concluded overall that “the evidence supporting the use of inositol in the management of PCOS is limited and inconclusive” — language the guideline authors chose deliberately rather than a stronger endorsement. That does not mean inositol does nothing; it means the fertility-specific evidence has not cleared the bar the guideline sets for a first-line recommendation, which is why it sits alongside, not ahead of, letrozole in most guideline-based care.

If you are already taking inositol or considering metformin for reasons beyond fertility — insulin resistance, cycle regularity, or metabolic markers — that is a separate, legitimate use case from what this table evaluates; the table above answers a narrower question specifically about fertility-outcome evidence.

Who This Will Not Help, and What to Do Instead

Everything above describes anovulatory infertility specifically — the pattern where PCOS itself is the reason a pregnancy is not occurring. None of it will help if infertility has a different or additional cause: a blocked fallopian tube, a uterine structural problem, or a male-factor issue with sperm count or motility, all of which were deliberately screened out of the major trials cited on this page before anyone was enrolled. If a full year of trying (or six months at 35 or older) has passed without a pregnancy, a proper work-up checks for these causes directly rather than assuming PCOS is the whole explanation.

It also will not help if the guideline’s early steps have already had a fair, monitored trial and not worked. Repeating the same first-line approach for months longer, or trying to self-adjust a regimen without a specialist, is not what the guideline recommends at that point — when to escalate, and to whom, is covered here. Genuine non-response after several monitored cycles is a reason to discuss second-line options — combining medications, adding gonadotropins, or a specialist referral for IVF — with the clinician managing your case, not a reason to try a longer course of the same first-line drug on your own initiative. And it will not help to treat any single lab value — an AMH result, an ultrasound follicle count, one positive ovulation test — as a verdict on your fertility in isolation. AMH specifically is a supply marker, not a quality or timing guarantee, and the most reliable way to know whether ovulation actually happened on a given cycle is a confirmed temperature or progesterone pattern, not a single test strip.

Finally, none of the treatment-order guidance above changes once pregnancy happens — a separate set of guideline-based monitoring points applies through pregnancy itself, and PCOS carries a modestly higher, well-quantified miscarriage rate worth knowing rather than discovering after the fact. A prior PCOS pregnancy is also no guarantee the next one goes the same way — why secondary infertility differs the second time comes down to age, weight, and treatment-response variables that can shift between pregnancies. And when prenatal vitamins should actually start is earlier than a positive test, given how unpredictable a PCOS cycle makes the usual “wait for a late period” starting point.

Common questions